TherapeuticsMD Inc

TherapeuticsMD Inc

TXMD - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$20.83M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
TherapeuticsMD IncTherapeuticsMD Inc-95.7--1%-0.2
$-1.84

Current Fair Value

201.8% downside

Overvalued by 201.8% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$20.83 Million
Enterprise Value$17.20 Million
Earnings per Share$-0.05
Beta0.65
Outstanding Shares11,574,000

Return

Return on Equity-0.80%ROE
Return on Assets-0.58%
Return on Invested Capital-11.30%

Valuation & Multiples

P/E Ratio-95.74P/E Ratio
PEG133.22PEG
Price to Sales-Price to Sales
Price to Book Ratio0.91Price to Book Ratio
Enterprise Value to Revenue6.92
Enterprise Value to EBIT-4.68
Enterprise Value to Net Income-80
Total Debt to Enterprise0.32
Debt to Equity0.2Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 17, 2026
EPS Estimate
$-6.13
Consensus analyst estimate
Revenue Estimate
$19.77 M
Consensus analyst estimate

Next Earnings Call

Expected Date
November 17, 2026
EPS Estimate
$-6.13
Consensus analyst estimate
Revenue Estimate
$19.77 M
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-▼ 100.00%
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %0.00%▼ 31.68%
Total Invested$41▼ 100.00%
Investors Holding1▼ 46.00%

About TherapeuticsMD Inc

3,000 employees
CEO: Robert Finizio

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience th...

TherapeuticsMD Insider Information FAQ

Stockcircle tracks 3 top investors with a current 13F position in TherapeuticsMD. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 2 top investors increased or opened positions and 1 top investor reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.